← Back to Drug List

LANADELUMAB-FLYO INJ,SOLN

Clinical Criteria Summary

Exclusion Criteria

  • Angioedema or abdominal pain not associated with C1 inhibitor deficiency, including hereditary angioedema with normal C1 inhibitor (HAE nC1-INH)
  • Concomitant use with another prophylaxis agent for HAE (e.g., berotralstat, donidalorsen, or garadacimab)

Inclusion Criteria

  • Restricted to VA / VA Community Care allergy/immunology provider, dermatology provider, or locally designated expert
  • Diagnosis of Hereditary Angioedema Type 1 or 2 as established by laboratory testing
  • Long-term prophylaxis for HAE attacks or short-term prophylaxis prior to procedures or intubation

Diagnostic & Laboratory Requirements

  • C4 level below the limit of normal
  • AND one of the following: C1 inhibitor (C1-INH) antigenic level below the limit of normal OR C1-INH functional level below the limit of normal

Clinical Subtype Context

  • Hereditary angioedema with C1 inhibitor deficiency (HAE-C1INH), also identified as HAE types 1 and 2
  • Hereditary angioedema with normal C1 inhibitor (HAE-nC1-INH) caused by variants in genes such as FXII, PLG, KNG1, ANGPT1, MYOF, HS3ST6, CPN1, or DAB21P, or unidentified genetic causes

Source Documents